{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T20:43:50Z","timestamp":1770065030782,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"DOI":"10.7759\/cureus.102817","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T09:45:14Z","timestamp":1770025514000},"source":"Crossref","is-referenced-by-count":0,"title":["Beyond Weight Loss: Holistic Impacts of a Digital Weight Management Programme Integrating Tirzepatide"],"prefix":"10.7759","author":[{"given":"Lena M","family":"Sikorska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian N","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Earim","family":"Chaudry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Reisel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley K","family":"Clift","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metop.2025.100375","article-title":"Obesity: Prevalence, causes, consequences, management, preventive strategies and future research directions","volume":"27","author":"Ahmed SK","year":"2025","unstructured":"Ahmed SK, Mohammed RA. Obesity: Prevalence, causes, consequences, management, preventive strategies and future research directions. Metabol Open. 2025, 27:100375. 10.1016\/j.metop.2025.100375","journal-title":"Metabol Open"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-024-21061-z","article-title":"Prevalence of complications and comorbidities associated with obesity: a health insurance claims analysis","volume":"25","author":"Bae JP","year":"2025","unstructured":"Bae JP, Nelson DR, Boye KS, Mather KJ. Prevalence of complications and comorbidities associated with obesity: a health insurance claims analysis. BMC Public Health. 2025, 25:273. 10.1186\/s12889-024-21061-z","journal-title":"BMC Public Health"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-077139","article-title":"Holistic modelling as a catalyst for effective obesity policy","volume":"386","author":"McLaughlin J","year":"2024","unstructured":"McLaughlin J, Rejon CS, Bell M, Schwander B, Coulman K, McLeod H. Holistic modelling as a catalyst for effective obesity policy. BMJ. 2024, 386:e077139. 10.1136\/bmj-2023-077139","journal-title":"BMJ"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept","volume":"18","author":"Coskun T","year":"2018","unstructured":"Coskun T, Sloop KW, Loghin C, et al.. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018, 18:3-14. 10.1016\/j.molmet.2018.09.009","journal-title":"Mol Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.9217","article-title":"Tirzepatide for weight reduction in Chinese adults with obesity: the SURMOUNT-CN randomized clinical trial","volume":"332","author":"Zhao L","year":"2024","unstructured":"Zhao L, Cheng Z, Lu Y, et al.. Tirzepatide for weight reduction in Chinese adults with obesity: the SURMOUNT-CN randomized clinical trial. JAMA. 2024, 332:551-60. 10.1001\/jama.2024.9217","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s40519-025-01720-9","article-title":"The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis","volume":"30","author":"Radkhah H","year":"2025","unstructured":"Radkhah H, Rahimipour Anaraki S, Parhizkar Roudsari P, et al.. The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis. Eat Weight Disord. 2025, 30:10. 10.1007\/s40519-025-01720-9","journal-title":"Eat Weight Disord"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2023.08.010","article-title":"The antidepressant effects of GLP-1 receptor agonists: a systematic review and meta-analysis","volume":"32","author":"Chen X","year":"2024","unstructured":"Chen X, Zhao P, Wang W, Guo L, Pan Q. The antidepressant effects of GLP-1 receptor agonists: a systematic review and meta-analysis. Am J Geriatr Psychiatry. 2024, 32:117-27. 10.1016\/j.jagp.2023.08.010","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.orcp.2015.03.005","article-title":"Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide - A pilot study","volume":"9","author":"Robert SA","year":"2015","unstructured":"Robert SA, Rohana AG, Shah SA, Chinna K, Wan Mohamud WN, Kamaruddin NA. Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide - A pilot study. Obes Res Clin Pract. 2015, 9:301-4. 10.1016\/j.orcp.2015.03.005","journal-title":"Obes Res Clin Pract"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2023.100080","article-title":"Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: a retrospective cohort study","volume":"7","author":"Richards J","year":"2023","unstructured":"Richards J, Bang N, Ratliff EL, Paszkowiak MA, Khorgami Z, Khalsa SS, Simmons WK. Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: a retrospective cohort study. Obes Pillars. 2023, 7:100080. 10.1016\/j.obpill.2023.100080","journal-title":"Obes Pillars"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2020.03.009","article-title":"Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: a pilot study","volume":"14","author":"Da Porto A","year":"2020","unstructured":"Da Porto A, Casarsa V, Colussi G, Catena C, Cavarape A, Sechi L. Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: a pilot study. Diabetes Metab Syndr. 2020, 14:289-92. 10.1016\/j.dsx.2020.03.009","journal-title":"Diabetes Metab Syndr"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez JJ","year":"2022","unstructured":"Gorgojo-Mart\u00ednez JJ, Mezquita-Raya P, Carretero-G\u00f3mez J, et al.. Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2022, 12:145. 10.3390\/jcm12010145","journal-title":"J Clin Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2196\/69466","article-title":"Impact of digital engagement on weight loss outcomes in obesity management among individuals using GLP-1 and dual GLP-1\/GIP receptor agonist therapy: retrospective cohort service evaluation study","volume":"27","author":"Johnson H","year":"2025","unstructured":"Johnson H, Huang D, Liu V, Ammouri MA, Jacobs C, El-Osta A. Impact of digital engagement on weight loss outcomes in obesity management among individuals using GLP-1 and dual GLP-1\/GIP receptor agonist therapy: retrospective cohort service evaluation study. J Med Internet Res. 2025, 27:e69466. 10.2196\/69466","journal-title":"J Med Internet Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70244","article-title":"Digital engagement enhances dual GIP\/GLP-1 receptor agonist and GLP-1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety","volume":"28","author":"Johnson H","year":"2026","unstructured":"Johnson H, Clift AK, Reisel D, Huang DR. Digital engagement enhances dual GIP\/GLP-1 receptor agonist and GLP-1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety. Diabetes Obes Metab. 2026, 28:634-43. 10.1111\/dom.70244","journal-title":"Diabetes Obes Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s41347-019-00118-6","article-title":"Incorporating health behavior theory into mHealth: an examination of weight loss, dietary, and physical activity interventions","volume":"5","author":"Salwen-Deremer JK","year":"2020","unstructured":"Salwen-Deremer JK, Khan AS, Martin SS, Holloway BM, Coughlin JW. Incorporating health behavior theory into mHealth: an examination of weight loss, dietary, and physical activity interventions. J Tech Behav Sci. 2020, 5:51-60. 10.1007\/s41347-019-00118-6","journal-title":"J Tech Behav Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s10865-009-9239-y","article-title":"Using self-determination theory to promote physical activity and weight control: a randomized controlled trial in women","volume":"33","author":"Silva MN","year":"2010","unstructured":"Silva MN, Vieira PN, Coutinho SR, Minderico CS, Matos MG, Sardinha LB, Teixeira PJ. Using self-determination theory to promote physical activity and weight control: a randomized controlled trial in women. J Behav Med. 2010, 33:110-22. 10.1007\/s10865-009-9239-y","journal-title":"J Behav Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4603(82)90024-7","article-title":"The assessment of binge eating severity among obese persons","volume":"7","author":"Gormally J","year":"198219820101","unstructured":"Gormally J, Black S, Daston S, Rardin D. The assessment of binge eating severity among obese persons. Addict Behav. 198219820101, 7:47-55. 10.1016\/0306-4603(82)90024-7","journal-title":"Addict Behav"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke K","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001, 16:606-13. 10.1046\/j.1525-1497.2001.016009606.x","journal-title":"J Gen Intern Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-16. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03340-2","article-title":"Real-world weight loss observed with semaglutide and tirzepatide in patients with overweight or obesity and without type 2 diabetes (SHAPE)","volume":"42","author":"Ng CD","year":"2025","unstructured":"Ng CD, Divino V, Wang J, Toliver JC, Buss M. Real-world weight loss observed with semaglutide and tirzepatide in patients with overweight or obesity and without type 2 diabetes (SHAPE). Adv Ther. 2025, 42:5468-80. 10.1007\/s12325-025-03340-2","journal-title":"Adv Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-022-04005-y","article-title":"Physical and mental health outcomes of an integrated cognitive behavioural and weight management therapy for people with an eating disorder characterized by binge eating and a high body mass index: a randomized controlled trial","volume":"22","author":"Hay P","year":"2022","unstructured":"Hay P, Palavras MA, da Luz FQ, et al.. Physical and mental health outcomes of an integrated cognitive behavioural and weight management therapy for people with an eating disorder characterized by binge eating and a high body mass index: a randomized controlled trial. BMC Psychiatry. 2022, 22:355. 10.1186\/s12888-022-04005-y","journal-title":"BMC Psychiatry"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.0679","article-title":"Glucagon-like peptide 1 receptor agonists and mental health: a systematic review and meta-analysis","volume":"82","author":"Pierret AC","year":"2025","unstructured":"Pierret AC, Mizuno Y, Saunders P, et al.. Glucagon-like peptide 1 receptor agonists and mental health: a systematic review and meta-analysis. JAMA Psychiatry. 2025, 82:643-53. 10.1001\/jamapsychiatry.2025.0679","journal-title":"JAMA Psychiatry"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.2","article-title":"Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies","volume":"67","author":"Luppino FS","year":"2010","unstructured":"Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW, Zitman FG. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010, 67:220-9. 10.1001\/archgenpsychiatry.2010.2","journal-title":"Arch Gen Psychiatry"},{"key":"ref23","unstructured":"NICE Clinical Guidelines. Overweight and obesity management. (2026). Accessed. 2026: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK612416\/."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s44220-025-00390-x","article-title":"An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders","volume":"3","author":"De Giorgi R","year":"202520250301","unstructured":"De Giorgi R, Ghenciulescu A, Dziwisz O, et al.. An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders. Nature Mental Health. 202520250301, 3:354-73. 10.1038\/s44220-025-00390-x","journal-title":"Nature Mental Health"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-024-02392-0","article-title":"A qualitative study of the mental health outcomes in people being treated for obesity and type 2 diabetes with glucagon-like peptide-1 receptor agonists","volume":"62","author":"Pierret AC","year":"2025","unstructured":"Pierret AC, Benton M, Sen Gupta P, Ismail K. A qualitative study of the mental health outcomes in people being treated for obesity and type 2 diabetes with glucagon-like peptide-1 receptor agonists. Acta Diabetol. 2025, 62:731-42. 10.1007\/s00592-024-02392-0","journal-title":"Acta Diabetol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/life15091422","article-title":"GLP-1 receptor agonists in mood disorders: a psychiatric perspective","volume":"15","author":"Carmellini P","year":"2025","unstructured":"Carmellini P, Cuomo A, Rescalli MB, Fagiolini A. GLP-1 receptor agonists in mood disorders: a psychiatric perspective. Life (Basel). 2025, 15:1422. 10.3390\/life15091422","journal-title":"Life (Basel)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/eat.20376","article-title":"Binge eating in the bariatric surgery population: a review of the literature","volume":"40","author":"Niego SH","year":"2007","unstructured":"Niego SH, Kofman MD, Weiss JJ, Geliebter A. Binge eating in the bariatric surgery population: a review of the literature. Int J Eat Disord. 2007, 40:349-59. 10.1002\/eat.20376","journal-title":"Int J Eat Disord"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03774-9","article-title":"Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial","volume":"31","author":"Martin CK","year":"2025","unstructured":"Martin CK, Carmichael OT, Carnell S, et al.. Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nat Med. 2025, 31:3141-50. 10.1038\/s41591-025-03774-9","journal-title":"Nat Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.2196\/57577","article-title":"Behavior change techniques within digital interventions for the treatment of eating disorders: systematic review and meta-analysis","volume":"11","author":"Thomas PC","year":"2024","unstructured":"Thomas PC, Curtis K, Potts HW, Bark P, Perowne R, Rookes T, Rowe S. Behavior change techniques within digital interventions for the treatment of eating disorders: systematic review and meta-analysis. JMIR Ment Health. 2024, 11:e57577. 10.2196\/57577","journal-title":"JMIR Ment Health"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/441625-beyond-weight-loss-holistic-impacts-of-a-digital-weight-management-programme-integrating-tirzepatide","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T09:45:14Z","timestamp":1770025514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/441625-beyond-weight-loss-holistic-impacts-of-a-digital-weight-management-programme-integrating-tirzepatide"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.102817","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,2]]}}}